All In Biotech

Drug Trial Radar · NCT07672405

Sorfequiline-based Regimens in Adults With Newly Diagnosed Drug-sensitive Pulmonary TB

A Phase 2b, Randomised, Multi-center, Partially Blinded Trial Assessing the Safety and Efficacy of Regimens Containing Sorfequiline, Pretomanid and Linezolid in Adults With Newly Diagnosed, Drug-sensitive, Smear Positive Pulmonary Tuberculosis

Last checked: Nov 20, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Jul 9, 2026

Primary completion

May 28, 2027

Study completion Jun 24, 2028

Sponsor

Lead sponsor
Global Alliance for TB Drug DevelopmentAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 26, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this interventional trial is to evaluate the safety and efficacy of the loading dose regimen 200/100SPaL-4/13 weeks, and the 100SPaL -17 weeks regimen in adults with newly diagnosed, drug-sensitive, smear-positive pulmonary tuberculosis. Participants (18-65 years) will be randomised 1:1, stratified by country and disease severity, to receive either : 1. a sorfequiline loading-dose regimen (200 mg daily for 4 weeks followed by 100 mg daily for 13 weeks) plus pretomanid 200 mg and linezolid 600 mg daily, or 2. sorfequiline 100 mg daily for 17 weeks plus pretomanid 200 mg and linezolid 600 mg daily. Study treatment is administered orally once daily with food. The primary objective is to assess safety through 17 weeks of treatment, including treatment-emergent adverse events, ECG findings, vital signs, laboratory assessments, visual acuity, and peripheral neuropathy. Secondary objectives include assessments of efficacy (time to stable sputum culture conversion; favorable outcome and treatment failure/relapse at 26 and 52 weeks after end of treatment) and pharmacokinetics of trial drugs, with exploratory analyses including predictors of culture conversion, exposure-response relationships, and quality of life.

Conditions

  • Tuberculosis, Pulmonary

Interventions

  • sorfequilineDrug

    Two sorfequiline 100mg tablets taken once daily for 4 weeks then one sorfequiline taken once daily for 13 weeks OR one sorfequiline 100mg tablet taken once daily for 17 weeks (with one 100mg sorfequiline placebo tablet for the first 4 weeks)

  • PretomanidDrug

    one 200mg tablet taken once daily for 17 weeks

  • LinezolidDrug

    one 600mg tablet taken once daily for 17 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and characterization of treatment-emergent adverse events (TEAEs)Time frame: Through 17 weeks of treatment

Locations

12 sites in 2 countries. Site status is shown where the registry gives one.

  • Synergy Biomed Research Institute

    East London, South Africa · Not yet recruiting

  • Durban International Clinical Research Site

    Wentworth, Durban, South Africa · Recruiting

  • Isango Lethemba TB Research Unit

    Port Elizabeth, Eastern Cape, South Africa · Recruiting

  • Setshaba Research Centre

    Soshanguve, Gauteng, South Africa · Recruiting

  • University of Capetown Lung Institute

    Cape Town, Mowbray, South Africa · Recruiting

  • The Aurum Institute, Rustenburg

    Rustenburg, North West, South Africa · Recruiting

  • Madiberg Centre for Research

    Brits, North West Provinvce, South Africa · Recruiting

  • Perinatal HIV Research Unit, Tshepong Hospital

    Klerksdorp, Northwest Province, South Africa · Not yet recruiting

  • INUKA Africa

    Dar es Salaam, Tanzania · Not yet recruiting

  • NIMR-Mbeya

    Mbeya, Tanzania · Not yet recruiting

  • Kilimanjaro Clinical Research Institute(KCRI)

    Moshi, Tanzania · Not yet recruiting

  • NIMRI-Mwanza

    Mwanza, Tanzania · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.